Unfortunately, shareholders of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) have suffered share price declines over the last year. To wit the share price is down 54% in that time. To make matters worse, ...

Wells Fargo launched its coverage of Sarepta Therapeutics (NASDAQ:SRPT) with an Overweight recommendation, citing commercial ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today shared updates ...

The past six months haven’t been great for Sarepta Therapeutics. It just made a new 52-week low of $52, and shareholders have ...

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price ...

There are 956 funds or institutions reporting positions in Sarepta Therapeutics ... the author and do not necessarily reflect those of Nasdaq, Inc. Fintel is a leading provider of financial ...

One of Sarepta's biggest challengers is Solid Biosciences (NASDAQ: SLDB). Below are the details on what has transpired recently surrounding ELEVIDYS. Solid Biosciences may have an opportunity to ...

The law firm of Kessler Topaz Meltzer & Check, LLP ( is currently investigating potential violations of the federal ...

Morgan Stanley analyst Michael Ulz maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of ...

Orion Portfolio Solutions LLC lessened its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 17.7% during the fourth quarter, according to the company in its most ...

Wells Fargo launched its coverage of Sarepta Therapeutics (NASDAQ:SRPT) with an Overweight recommendation, citing commercial prospects for Elevidys, a gene therapy developed by SRPT with Roche ...